5`S-LNA nucleotides and oligonucleotides

Abstract

The invention relates to a compound of formula (I) wherein R2 and R4 are joined and together form a group, such a —CH2O—. The compound of formula (I) can be used in the manufacture of 5'S-LNA oligonucleotides as antisense drugs.

1 . A compound of formula (I) 
       
         
           
           
               
               
           
         
         wherein 
         R 1  is a phosphate protecting group; 
         R 2  and R 4  together form —CH 2 O—, —CH 2 NH—, —CH 2 S—, —CH 2 N(OR′)—, —CHCH 3 O—, C(CH 3 ) 2 O, —CH 2 C(═CH 2 )—, —CHCH 3 C(═CH 2 )—, —CHCH 3 S—, —CH 2 NR p —, —CH 2 CH 2 O—, —CH 2 CH 2 CH 2 O—, —CH 2 OCH 2 —, —CH(CH 2 OCH 3 )O—, —CH(CH 2 CH 3 )O— or —CH 2 OCH 2 O—; 
         R 3  is dialkylamino; 
         R 5  is a thiohydroxyl protecting group; 
         each R p  is alkyl; and 
         Nu is a nucleobase optionally comprising a protected primary amino group. 
       
     
     
         2 . A compound according to  claim 1 , wherein R 1  is cyanoethyl or methyl. 
     
     
         3 . A compound according to  claim 1 , wherein R 2  and R 4  together form —CH 2 O—. 
     
     
         4 . A compound according to  claim 1 , wherein R 3  is diisopropylamino. 
     
     
         5 . A compound according to  claim 1 , wherein R 5  is trityl, 4-methoxytrityl, 4,4′-dimethoxytrityl or 4,4′,4″-trimethoxytrityl. 
     
     
         6 . A compound according to  claim 1 , wherein each Rp is independently methyl, ethyl or propyl. 
     
     
         7 . A compound according to  claim 1 , wherein Nu is adenine, guanine, cytosine, 5-methyl-cytosine, thymine or uracil. 
     
     
         8 . A compound according to  claim 1 , wherein Nu is (A), (B), (C) or (D) 
       
         
           
           
               
               
           
         
       
       wherein R 6  is hydrogen or a protecting group of the amino group to which it is attached. 
     
     
         9 . A compound according to  claim 8 , wherein the protecting group of the amino group is benzoyl, dimethylformamide, acetyl or isobutyryl. 
     
     
         10 . A compound according to  claim 1 , wherein Nu is (A1), (B1) or (C1) 
       
         
           
           
               
               
           
         
       
     
     
         11 . A process for the manufacture of a compound of formula (I) as defined in  claim 1 , comprising the reaction of a compound of formula (II) 
       
         
           
           
               
               
           
         
         in the presence of P(R 3 ) 2 OR 1  and an oligonucleotide synthesis activator, wherein 
         R 1  is a phosphate protecting group; 
         R 2  and R 4  together form —CH 2 O—, —CH 2 NH—, —CH 2 S—, —CH 2 N(OR′)—, —CHCH 3 O—, C(CH 3 ) 2 O, —CH 2 C(═CH 2 )—, —CHCH 3 C(═CH 2 )—, —CHCH 3 S—, —CH 2 NR p —, —CH 2 CH 2 O—, —CH 2 CH 2 CH 2 O—, —CH 2 OCH 2 —, —CH(CH 2 OCH 3 )O—, —CH(CH 2 CH 3 )O— or —CH 2 OCH 2 O—; 
         R 3  is dialkylamino; 
         R 5  is a thiohydroxyl protecting group; 
         and each R p  is alkyl. 
       
     
     
         12 . A process according to  claim 11 , wherein the compound of formula (II) is obtained by the reaction of a compound of formula (III) 
       
         
           
           
               
               
           
         
         in the presence of R 5 X 1  and a base, wherein 
         R 2  and R 4  together form —CH 2 O—, —CH 2 NH—, —CH 2 S—, —CH 2 N(OR′)—, —CHCH 3 O—, C(CH 3 ) 2 O, —CH 2 C(═CH 2 )—, —CHCH 3 C(═CH 2 )—, —CHCH 3 S—, —CH 2 NR p —, —CH 2 CH 2 O—, —CH 2 CH 2 CH 2 O—, —CH 2 OCH 2 —, —CH(CH 2 OCH 3 )O—, —CH(CH 2 CH 3 )O— or —CH 2 OCH 2 O—; 
         R 3  is dialkylamino; 
         R 5  is a thiohydroxyl protecting group; 
         each R p  is alkyl; 
         Nu is a nucleobase optionally comprising a protected primary amino group 
       
       and wherein X 1  is a leaving group. 
     
     
         13 . A process according to  claim 12 , wherein the compound of formula (III) is obtained by the hydrolysis of a compound of formula (IV) 
       
         
           
           
               
               
           
         
         wherein 
         R 7  is alkyl, aryl, arylalkyl, substituted aryl or substituted arylalkyl, wherein substituted aryl and substituted arylalkyl are aryl and arylalkyl substituted on the aryl with one to three substitutents independently selected from alkyl, alkoxy and halogen. 
       
     
     
         14 . A process according to  claim 13 , wherein R 7  is phenyl. 
     
     
         15 . A process according to  claim 13 , wherein the compound of formula (IV) is obtained by the reaction of a compound of formula (V) 
       
         
           
           
               
               
           
         
         in the presence of R 7 COSH, a phosphine and a dehydrating agent, wherein R 7  is alkyl, aryl, arylalkyl, substituted aryl or substituted arylalkyl, wherein substituted aryl and substituted arylalkyl are aryl and arylalkyl substituted on the aryl with one to three substitutents independently selected from alkyl, alkoxy and halogen. 
       
     
     
         16 . A process according to  claim 15 , wherein the compound of formula (V) is obtained by the removal of the hydroxyl protecting group R 5  of a compound of formula (VI) 
       
         
           
           
               
               
           
         
         wherein R 5  is a hydroxyl protecting group. 
       
     
     
         17 . A process according to  claim 11 , wherein the compound of formula (II) is obtained by the reaction of a compound of formula (VII) 
       
         
           
           
               
               
           
         
         in the presence of a base, a nucleophile and a compound of formula (VIII) 
       
       
         
           
           
               
               
           
         
         wherein 
         R 8  is a leaving group; 
         R 9  is alkyl. 
       
     
     
         18 . A process according to  claim 17 , wherein the compound of formula (VII) is obtained by the reaction of a compound of formula (V) 
       
         
           
           
               
               
           
         
         in the presence of R 8 X 2  and a non-nucleophilic base, wherein X 2  is a leaving group and R 8  is a group capable of forming a leaving group together with the 5′ hydroxyl oxygen atom of the compound of formula (V). 
       
     
     
         19 . A process according to  claim 17 , wherein the compound of formula (VIII) is obtained by the reaction of R 5 X 3  in the presence of R 9 C(O)SH X 3  is a leaving group. 
     
     
         20 . A process according to  claim 11 , wherein the oligonucleotide synthesis activator is an azole. 
     
     
         21 . A process according to  claim 11 , wherein the oligonucleotide synthesis activator is 1H-tetrazole, 5-nitrophenyl-1H-tetrazole (NPT), 5-ethylthio-1H-tetrazole (ETT), 5-benzylthio-1H-tetrazole (BTT), 5-methylthio-1H-tetrazole (MTT), 5-mercapto-tetrazoles (MCT) or 4,5-dicyanoimidazole (DCI). 
     
     
         22 . A process according to  claim 17 , wherein the nucleophile is NaOH, KOH, NaOMe, KOMe, methylamine or NH 3 . 
     
     
         23 . A process according to  claim 15 , wherein the dehydrating agent is diethyl azodicarboxylate or diisopropyl azodicarboxylate. 
     
     
         24 . A process according to  claim 12 , wherein the phosphine is triphenylphosphine or trimethylphosphine. 
     
     
         25 . A process according to  claim 16 , wherein the removal of the hydroxyl protecting group R 5  of a compound of formula (VI) is done by the reaction of a compound of formula (VI) in the presence of acid. 
     
     
         26 . A process according to  claim 25 , wherein the acid is perchloroacetic acid, acetic acid, chloroacetic acid, dichloroacetic acid or trifluoroacetic acid. 
     
     
         27 . (canceled) 
     
     
         28 . (canceled) 
     
     
         29 . (canceled) 
     
     
         30 . A compound according to  claim 1  selected from
 N-{9-[1-({[bis(4-methoxyphenyl)(phenyl)methyl]sulfanyl}methyl)-7-({[bis(propan-2-yl)amino](2-cyanoethoxy)phosphanyl}oxy)-2,5-dioxabicyclo[2.2.1]heptan-3-yl]-9H-purin-6-yl}benzamide; 
 3-[({[1-({[bis(4-methoxyphenyl)(phenyl)methyl]sulfanyl}methyl)-3-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-2,5-dioxabicyclo[2.2.1]heptan-7-yl]oxy}[bis(propan-2-yl)amino]phosphanyl)oxy]propanenitrile; 
 N′-{9-[1-({[bis(4-methoxyphenyl)(phenyl)methyl]sulfanyl}methyl)-7-({[bis(propan-2-yl)amino](2-cyanoethoxy)phosphanyl}oxy)-2,5-dioxabicyclo[2.2.1]heptan-3-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-N,N-dimethylmethanimidamide; and 
 N-{1-[1-({[bis(4-methoxyphenyl)(phenyl)methyl]sulfanyl}methyl)-7-({[bis(propan-2-yl)amino](2-cyanoethoxy)phosphanyl}oxy)-2,5-dioxabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-1,2-dihydropyrimidin-4-yl}benzamide. 
 
     
     
         31 . A compound selected from
 N-(9-{1-[(benzoylsulfanyl)methyl]-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptan-3-yl}-9H-purin-6-yl)benzamide;   N-{9-[7-hydroxy-1-(sulfanylmethyl)-2,5-dioxabicyclo[2.2.1]heptan-3-yl]-9H-purin-6-yl}benzamide;   N-{9-[1-({[bis(4-methoxyphenyl)(phenyl)methyl]sulfanyl}methyl)-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptan-3-yl]-9H-purin-6-yl}benzamide;   1-[1-({[bis(4-methoxyphenyl)(phenyl)methyl]sulfanyl}methyl)-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptan-3-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione;   N′-(9-{1-[(benzoylsulfanyl)methyl]-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptan-3-yl}-6-oxo-6,9-dihydro-1H-purin-2-yl)-N,N-dimethylmethanimidamide;   N′-{9-[7-hydroxy-1-(sulfanylmethyl)-2,5-dioxabicyclo[2.2.1]heptan-3-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-N,N-dimethylmethanimidamide;   N′-{9-[1-({[bis(4-methoxyphenyl)(phenyl)methyl]sulfanyl}methyl)-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptan-3-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-N,N-dimethylmethanimidamide;   N-(1-{1-[(benzoylsulfanyl)methyl]-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptan-3-yl}-5-methyl-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide;   N-{1-[7-hydroxy-1-(sulfanylmethyl)-2,5-dioxabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-1,2-dihydropyrimidin-4-yl}benzamide and;   N-{1-[1-({[bis(4-methoxyphenyl)(phenyl)methyl]sulfanyl}methyl)-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-1,2-dihydropyrimidin-4-yl}benzamide.   
     
     
         32 . (canceled) 
     
     
         33 . An oligonucleotide comprising a fragment of formula (IX) 
       
         
           
           
               
               
           
         
         wherein 
         R 2  and R 4  together form —CH 2 O—, —CH 2 NH—, —CH 2 S—, —CH 2 N(OR′)—, —CHCH 3 O—, —C(CH 3 ) 2 O—, —CH 2 C(═CH 2 )—, —CHCH 3 C(═CH 2 )—, —CHCH 3 S—, —CH 2 NR p —, —CH 2 CH 2 O—, —CH 2 CH 2 CH 2 O—, —CH 2 OCH 2 —, —CH(CH 2 OCH 3 )O—, —CH(CH 2 CH 3 )O— or —CH 2 OCH 2 O—; wherein each R′ is alkyl; and 
         Nu is a nucleobase optionally comprising a protected primary amino group. 
       
     
     
         34 . A method for the manufacture of an oligonucleotide comprising a fragment of formula (IX) as defined in  claim 33  comprising the following steps:
 (a) Providing a solid support comprising:
 a hydroxyl group; 
 a nucleotide comprising a hydroxyl group; or 
 an oligonucleotide comprising a hydroxyl group; 
 
 (b) Coupling a compound according to  claim 1 , a nucleotide, a locked nucleic acid nucleotide, a 2′-sugar modified nucleotide, a 3'S-DNA or a 3'S-LNA to the hydroxyl group of said solid support; 
 (c) Oxidizing or thiooxydizing the product obtained from (b); 
 (d) optionally capping unreacted hydroxyl groups of the product obtained from step (c); 
 (e) Optionally removing hydroxyl protecting groups or thiohydroxyl protecting groups from the product obtained from step (c) or (d); 
 (f) Optionally repeating steps (b) to (e); 
 (g) Optionally removing any remaining protecting groups from the product obtained from any one of steps (c) to (f); and 
 (h) Optionally cleaving the oligonucleotide from the solid support. 
 
     
     
         35 . (canceled)